Advanced cancer therapy: unlocking the potential of small molecule inhibitors

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Cancer remains a leading global cause of death, with current treatments like chemotherapy having significant adverse effects.
• Targeted therapeutic medicines, particularly small molecules, are increasingly adopted due to improved efficacy and safety profiles.
• Small molecules offer advantages including oral administration and intracellular penetration, targeting key molecular pathways selectively.

Purpose of the Study:

• To review small molecules as anticancer scaffolds.
• To guide the future design of novel antineoplastic compounds.
• To highlight the importance of structure-activity relationship (SAR) studies, preclinical, and clinical data in anticancer drug development.

Main Methods:

• Review of existing literature on small molecules in cancer therapy.
• Analysis of structure-activity relationship (SAR) studies.
• Examination of preclinical and clinical data for small molecule anticancer agents.

Main Results:

• Small molecules demonstrate significant potential as anticancer scaffolds due to their selectivity and ability to target intracellular pathways.
• Thorough analysis of SAR, preclinical, and clinical data is crucial for advancing anticancer drug development.
• Approved small molecule drugs represent successful examples of targeted cancer therapy.

Conclusions:

• Small molecules represent a promising class of drugs for developing next-generation anticancer therapies.
• Further investigation into SAR and clinical outcomes will lead to more potent, selective, and safer anticancer agents.
• The development of novel chemotherapeutic drugs is essential for treating disseminated cancers.